BioCentury
ARTICLE | Clinical News

Resverlogix plummets on ASSURE miss

June 28, 2013 1:17 AM UTC

Shares of Resverlogix Corp. (TSX:RVX) fell C$2.92 (93%) to C$0.23 on Thursday after the company said twice-daily oral RVX-208 missed the primary endpoint of reducing atheroma volume in the Phase IIb ASSURE trial to treat atherosclerosis in patients with acute coronary artery disease (CAD). RVX-208 led to a 0.4% reduction in atheroma volume from baseline to week 26 as measured by intravascular ultrasound (p=0.08); the threshold to meet the primary endpoint was a 0.6% reduction. The double-blind, placebo-controlled, international trial was led by the Cleveland Clinic and enrolled 324 high-risk CAD patients with low levels of HDL-C.

Resverlogix said it plans to analyze the full data set "over the coming weeks and months" to determine whether it will continue development of RVX-208 in cardiovascular disease. The inhibitor of the BET family of bromodomain-containing proteins, including bromodomain containing 4 (BRD4), is also in Phase II testing for pre-diabetes. ...